Early impact of maternal RSV vaccination on bronchiolitis hospitalisation and critical care admissions in infants under age 3 months, England, September 2024 to March 2026

Journal article

We conducted a time series analysis of hospitalisation and critical care admissions to evaluate the impact of maternal respiratory syncytial virus (RSV) vaccination in England from September 2024 to March 2026 in infants < 3 months of age. All bronchiolitis admissions decreased by 39.3% (IRR: 0.607, 95% CI: 0.576-0.640), and RSV bronchiolitis admissions by 62.6% (IRR: 0.374, 95% CI: 0.344-0.407). We estimated a 41.0% reduction in bronchiolitis critical care admissions (IRR: 0.590, 95% CI: 0.531-0.657). Maternal vaccine coverage was 55.1%. These findings support efforts to expand vaccine uptake.

Authors: Broad, J; Wilson, M; Borjas-Howard, J; Voysey, M; Drysdale, SB

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: European Centre for Disease Prevention and Control
• Journal: Eurosurveillance: Europe's journal on infectious disease surveillance, epidemiology, prevention and control
• Volume: 31
• Issue: 36
• Publication date: 2026-09-10
• DOI: 10.2807/1560-7917.ES.2026.31.36.2600752
• EISSN: 1025-496X
• ISSN: 1560-7917
• Language: English
• Keywords: Intensive care; Bronchiolitis; Vaccination; Coronavirus disease 2019 (COVID-19); Respiratory system; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Acute Bronchiolitis